Novartis Pharmaceuticals UK awarded an Innovation Passport for Investigational Oral Therapy Iptacopan (LNP023)
SUMMARY: Iptacopan has been awarded the Innovation Passport for the treatment of C3 glomerulopathy (C3G) and is currently being investigated in a…